PR Newswire
LAS VEGAS, Feb. 3, 2026
The insulin resistance market is expected to grow steadily over the forecast period (2026-2036). According to DelveInsight’s analysis, this growth is driven by the rising global prevalence of obesity and type 2 diabetes, increasing awareness of insulin resistance as a central pathophysiologic driver of multiple metabolic disorders. In addition, the emergence of novel disease-modifying and insulin-sensitizing therapies such as OrsoBio’s TLC-3595, Eli Lilly’s Retatrutide, AdipoPharma’s PATAS, and others is expected to further expand the market.
LAS VEGAS, Feb. 3, 2026 /PRNewswire/ — DelveInsight’s Insulin Resistance Market Insights report includes a comprehensive understanding of current treatment practices, insulin resistance emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Insulin Resistance Market Summary
- The total insulin resistance treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounts for the largest market size of insulin resistance, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
- Globally, the pooled prevalence of Insulin resistance was estimated at 26.53% in 2025, underscoring its widespread impact across populations.
- Leading insulin resistance companies, such as OrsoBio, Eli Lilly, AdipoPharma, Amgen, and others, are developing new insulin resistance treatment drugs that can be available in the insulin resistance market in the coming years.
- The promising insulin resistance therapies in clinical trials include TLC-3595, Retatrutide, PATAS, Maridebart cafraglutide, and others.
Discover what is the global insulin resistance market size and forecast to 2036 @ https://www.delveinsight.com/sample-request/insulin-resistance-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Insulin Resistance Market
- Rising Insulin Resistance Prevalence: The total prevalent cases of insulin resistance will rise steadily, supported by increasing cardio metabolic multimorbidity, earlier onset of metabolic dysfunction in younger adults, persistent socioeconomic and lifestyle risk factors, greater survival of patients with chronic metabolic disease, and expanding use of laboratory-based markers that capture subclinical insulin resistance.
- Advancements in Therapeutic Options: Innovative drug classes, such as GLP-1 receptor agonists and SGLT2 inhibitors, that improve insulin sensitivity and support weight management are being widely adopted, expanding treatment options.
- Launch of Emerging Insulin Resistance Drugs: The dynamics of the insulin resistance market are expected to change in the coming years due to the launch of emerging therapies such as TLC-3595 (OrsoBio), Retatrutide (Eli Lilly), PATAS (AdipoPharma), Maridebart cafraglutide (Amgen), and others.
Insulin Resistance Market Analysis
- Lifestyle modification remains the preferred first-line management for insulin resistance across major guidelines, including those from the United States (ADA/AACE), the United Kingdom (NICE), and Germany/EU (EASD/DDG).
- When lifestyle interventions are insufficient, pharmacologic treatment typically includes insulin sensitizers and incretin-based therapies.
- Metformin remains the cornerstone of therapy across all major guidelines, improving hepatic and peripheral insulin sensitivity while delaying progression to type 2 diabetes.
- Pioglitazone, a thiazolidinedione, enhances insulin sensitivity in adipose tissue and muscle and is selectively used in patients with severe insulin resistance or NAFLD/MASH, despite limitations such as weight gain and edema.
- In Japan, Imeglimin (TWYMEEG) represents a novel mitochondrial-targeted therapy that improves both insulin sensitivity and insulin secretion.
- GLP-1 receptor agonists and dual incretin therapies, including semaglutide (OZEMPIC, RYBELSUS, WEGOVY) and tirzepatide (MOUNJARO, ZEPBOUND), are increasingly adopted due to their strong effects on weight loss, insulin sensitivity, and cardiometabolic risk reduction.
- Adjunctive agents such as DPP-4 inhibitors, SGLT-2 inhibitors, and alpha-glucosidase inhibitors are used to optimize metabolic control but do not primarily target insulin resistance.
- The insulin resistance treatment landscape is evolving beyond currently approved therapies, with growing emphasis on disease-modifying approaches.
- Late-stage and emerging pipeline candidates, including TLC-3595 (OrsoBio) and PATAS (AdipoPharma), aim to directly address insulin resistance by targeting fatty acid oxidation, adipocyte dysfunction, and insulin-independent glucose uptake.
- There are currently no approved therapies specifically indicated for insulin resistance as a standalone condition, representing a substantial unmet medical need and a significant market opportunity for novel agents capable of restoring insulin sensitivity and altering the progression of metabolic disease.
Insulin Resistance Competitive Landscape
Some of the insulin resistance drugs in clinical trials include TLC-3595 (OrsoBio), Retatrutide (Eli Lilly), PATAS (AdipoPharma), Maridebart cafraglutide (Amgen), and others.
OrsoBio’s TLC-3595 is a first-in-class, selective inhibitor of acetyl-CoA carboxylase 2 (ACC2) under development to enhance insulin sensitivity in individuals with type 2 diabetes. It works by promoting fatty acid oxidation and lowering ectopic lipid buildup in skeletal muscle and the liver, and is also being investigated for potential benefits in heart failure with preserved ejection fraction (HFpEF).
Eli Lilly’s Retatrutide is a once-weekly investigational triple-agonist therapy engineered to simultaneously activate GIP, GLP-1, and glucagon receptors. Eli Lilly is assessing Retatrutide in multiple Phase III studies to evaluate its safety and effectiveness across a wide spectrum of cardiometabolic and obesity-associated disorders.
The anticipated launch of these emerging therapies are poised to transform the insulin resistance market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the insulin resistance market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which companies are leading the insulin resistance market @ Insulin Resistance Drugs Market
Recent Developments in the Insulin Resistance Market
- In December 2025, Eli Lilly and Company announced positive topline results from its Phase III TRIUMPH-4 trial of Retatrutide, the investigational once-weekly GIP/GLP-1/glucagon triple hormone receptor agonist, which demonstrated significant weight loss and improvement in knee osteoarthritis pain, and noted that seven additional Phase III trials, including those in obesity and type 2 diabetes, are expected to be completed in 2026.
- In June 2025, AdipoPharma announced that PATAS, its novel insulin-sensitizing peptide targeting adipocyte dysfunction, was recognized at the American Diabetes Association’s 85th Annual Meeting in Chicago and featured through a company-submitted video highlighting its unique, disease-modifying approach to treating insulin resistance, the root cause of type 2 diabetes.
What is Insulin Resistance?
Insulin resistance is a condition in which the body’s cells, especially those in muscles, fat, and the liver, do not respond effectively to insulin, a hormone that helps regulate blood sugar levels. When this happens, the pancreas compensates by producing more insulin to keep blood glucose within a normal range. Over time, this extra demand can strain the pancreas, leading to persistently high blood sugar and insulin levels. Insulin resistance is a key underlying factor in type 2 diabetes and is commonly associated with obesity, physical inactivity, genetics, and conditions like metabolic syndrome, increasing the risk of heart disease and other health complications.
Insulin Resistance Epidemiology Segmentation
The insulin resistance epidemiology section provides insights into the historical and current insulin resistance patient pool and forecasted trends for the leading markets. In the US, insulin resistance drives 70-90% of type 2 diabetes cases via beta-cell exhaustion and precedes metabolic syndrome in 25-40% of affected adults.
The insulin resistance treatment market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
- Total Prevalent Cases of Insulin Resistance
- Total Diagnosed Prevalent Cases of Insulin Resistance
- Gender-specific Cases of Insulin Resistance
- Age-specific Cases of Insulin Resistance
- Comorbidity-specific Cases of Insulin Resistance
- Treated Cases of Insulin Resistance
Insulin Resistance Market Forecast Report
Metrics
Details
Study Period
2022-2036
Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and
Japan].
Insulin Resistance Epidemiology Segmentation Total Prevalent Cases of Insulin Resistance, Total Diagnosed Prevalent Cases of Insulin
Resistance, Gender-specific Cases of Insulin Resistance, Age-specific Cases of Insulin
Resistance, Comorbidity-specific Cases of Insulin Resistance, and Treated Cases of Insulin
Resistance
Key Insulin Resistance Companies
OrsoBio, Eli Lilly, AdipoPharma, Amgen, and others
Key Insulin Resistance Therapies
TLC-3595, Retatrutide, PATAS, Maridebart cafraglutide, and others
Scope of the
Insulin Resistance
Market Report
- Therapeutic Assessment: Insulin Resistance current marketed and emerging therapies
- Insulin Resistance Market Dynamics: Key Market Forecast Assumptions of Emerging Insulin Resistance Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Insulin Resistance Market Access and Reimbursement
Download the report to understand what’s driving the insulin resistance market growth @ Insulin Resistance Market Forecast
Table of Contents
1
Insulin Resistance Market Key Insights
2
Insulin Resistance Market Report Introduction
3
Insulin Resistance Market Overview at a Glance
3.1 Insulin Resistance Market Share (%) Distribution by
Therapies by 2025
3.2 Insulin Resistance Market Share (%) Distribution by
Therapies by 2036
4
Executive Summary
5
Key events
6
Epidemiology and Market Methodology
7
Disease Background and Overview
7.1
Introduction
7.2
Signs and Symptoms
7.3
Diagnosis
7.4
Treatment and Management
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: The 7MM
8.3 Total Diagnosed Prevalent Cases of Insulin resistance in
the 7MM
8.4
The US
8.4.1 Total Prevalent Cases of Insulin Resistance in the US
8.4.2 Total Diagnosed Prevalent Cases of Insulin Resistance in
the US
8.4.3 Gender-specific Cases of Insulin Resistance in the US
8.4.4 Age-specific Cases of Insulin Resistance in the US
8.4.5 Comorbidity-specific Cases of Insulin resistance in the
US
8.4.6 Total Treated Cases of Insulin Resistance in the US
8.5
EU4 and the UK
8.6
Japan
9
Patient Journey
10
Emerging Insulin Resistance Therapies
10.1
Key Cross Competition
10.2
TLC-3595: OrsoBio
10.2.1
Product Description
10.2.2
Other Developmental Activities
10.2.3
Clinical Development
10.2.4
Clinical Trials Information
10.2.5
Safety and Efficacy
10.2.6
Analyst Views
10.3
Retatrutide: Eli Lilly
10.4
PATAS: AdipoPharma
List to be continued in the final report.
11
Insulin Resistance: Market Analysis
11.1
Key Findings
11.2
Insulin Resistance Market Outlook
11.3
Attribute Analysis
11.4 Key Insulin Resistance Market Forecast Assumptions
11.5
The 7MM Market Size
11.5.1 Total Market Size of Insulin Resistance in the 7MM
11.5.2 Market Size of Insulin Resistance by Therapies in the 7MM
11.6
The US Insulin Resistance Market Size
11.6.1 Total Market Size of Insulin Resistance in the US
11.6.2 Market Size of Insulin Resistance by Therapies in the US
11.7
EU4 and the UK Insulin Resistance Market Size
11.8
Japan Insulin Resistance Market Size
12 Insulin Resistance Market Access and Reimbursement
12.1
The United States
12.2
EU4 and the UK
12.3
Japan
12.4
Reimbursement Scenario in Insulin Resistance
13
KOL Views on Insulin Resistance
14
Insulin Resistance Market SWOT Analysis
15
Insulin Resistance Market Unmet Needs
16
Bibliography
17
Acronyms and Abbreviations
18
Insulin Resistance Market Report Methodology
Related Reports
Insulin Resistance Clinical Trial Analysis
Insulin Resistance Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key insulin resistance companies, including Boehringer Ingelheim, Eli Lilly and Company, Tonix Pharmaceuticals, Corbus Pharmaceuticals, Amolyt Pharma, Dompe Farmaceutici, among others.
Diabetes Market
Diabetes Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc., among others.
Obesity Market
Obesity Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obesity companies, including Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, among others.
Metabolic Dysfunction-Associated Steatohepatitis Market
Metabolic Dysfunction-Associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast
– 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MASH companies including Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Inc., Akero Therapeutics, Inc., 89bio, Inc., Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics Inc., Lipocine Inc., Viking Therapeutics, Inc., Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Inc., Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai) Co., Ltd., Hepion Pharmaceuticals, Inc., Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences Inc., Ionis Pharmaceuticals, Corcept Therapeutics, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur [email protected] +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/insulin-resistance-market-expected-to-witness-strong-growth-during-the-forecast-period-20262036–delveinsight-302677153.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…